vs

Side-by-side financial comparison of Amalgamated Financial Corp. (AMAL) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

Amalgamated Financial Corp. is the larger business by last-quarter revenue ($85.2M vs $57.6M, roughly 1.5× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 9.4%). Amalgamated Financial Corp. produced more free cash flow last quarter ($134.4M vs $-167.0M).

CI Financial is a Canadian investment management company based in Toronto, Ontario. It offers investment management and wealth management services targeted to high net worth retail investors, as well as brokerage and trading services to portfolio managers and institutional investors.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

AMAL vs PHAT — Head-to-Head

Bigger by revenue
AMAL
AMAL
1.5× larger
AMAL
$85.2M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+84.7% gap
PHAT
94.1%
9.4%
AMAL
More free cash flow
AMAL
AMAL
$301.4M more FCF
AMAL
$134.4M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AMAL
AMAL
PHAT
PHAT
Revenue
$85.2M
$57.6M
Net Profit
Gross Margin
86.7%
Operating Margin
39.0%
Net Margin
Revenue YoY
9.4%
94.1%
Net Profit YoY
71.6%
EPS (diluted)
$0.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMAL
AMAL
PHAT
PHAT
Q4 25
$85.2M
$57.6M
Q3 25
$85.6M
$49.5M
Q2 25
$80.9M
$39.5M
Q1 25
$77.0M
$28.5M
Q4 24
$77.9M
$29.7M
Q3 24
$81.0M
$16.4M
Q2 24
$78.5M
$7.3M
Q1 24
$78.3M
Net Profit
AMAL
AMAL
PHAT
PHAT
Q4 25
Q3 25
$26.8M
$-30.0M
Q2 25
$26.0M
$-75.8M
Q1 25
$25.0M
$-94.3M
Q4 24
Q3 24
$27.9M
$-85.6M
Q2 24
$26.8M
$-91.4M
Q1 24
$27.2M
Gross Margin
AMAL
AMAL
PHAT
PHAT
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
AMAL
AMAL
PHAT
PHAT
Q4 25
39.0%
Q3 25
42.9%
-30.8%
Q2 25
43.8%
-151.7%
Q1 25
45.1%
-276.5%
Q4 24
42.4%
Q3 24
47.2%
-433.0%
Q2 24
45.6%
-1055.4%
Q1 24
49.2%
Net Margin
AMAL
AMAL
PHAT
PHAT
Q4 25
Q3 25
31.3%
-60.5%
Q2 25
32.1%
-191.9%
Q1 25
32.5%
-330.7%
Q4 24
Q3 24
34.5%
-523.3%
Q2 24
34.1%
-1248.6%
Q1 24
34.8%
EPS (diluted)
AMAL
AMAL
PHAT
PHAT
Q4 25
$0.88
Q3 25
$0.88
$-0.41
Q2 25
$0.84
$-1.05
Q1 25
$0.81
$-1.31
Q4 24
$0.78
Q3 24
$0.90
$-1.32
Q2 24
$0.87
$-1.56
Q1 24
$0.89

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMAL
AMAL
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$291.2M
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$794.5M
$-438.2M
Total Assets
$8.9B
$259.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMAL
AMAL
PHAT
PHAT
Q4 25
$291.2M
$130.0M
Q3 25
$115.5M
$135.2M
Q2 25
$171.1M
$149.6M
Q1 25
$65.7M
$212.3M
Q4 24
$60.7M
$297.3M
Q3 24
$149.2M
$334.7M
Q2 24
$58.0M
$276.2M
Q1 24
$155.2M
Total Debt
AMAL
AMAL
PHAT
PHAT
Q4 25
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
AMAL
AMAL
PHAT
PHAT
Q4 25
$794.5M
$-438.2M
Q3 25
$775.6M
$-422.5M
Q2 25
$754.0M
$-405.8M
Q1 25
$736.0M
$-338.4M
Q4 24
$707.7M
$-253.6M
Q3 24
$698.2M
$-187.1M
Q2 24
$646.0M
$-233.8M
Q1 24
$616.8M
Total Assets
AMAL
AMAL
PHAT
PHAT
Q4 25
$8.9B
$259.1M
Q3 25
$8.7B
$240.3M
Q2 25
$8.6B
$250.2M
Q1 25
$8.3B
$294.2M
Q4 24
$8.3B
$378.3M
Q3 24
$8.4B
$387.0M
Q2 24
$8.3B
$319.4M
Q1 24
$8.1B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMAL
AMAL
PHAT
PHAT
Operating Cash FlowLast quarter
$135.8M
$-166.8M
Free Cash FlowOCF − Capex
$134.4M
$-167.0M
FCF MarginFCF / Revenue
157.8%
-290.0%
Capex IntensityCapex / Revenue
1.6%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$229.4M
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMAL
AMAL
PHAT
PHAT
Q4 25
$135.8M
$-166.8M
Q3 25
$39.5M
$-14.1M
Q2 25
$24.9M
$-62.7M
Q1 25
$34.2M
$-84.9M
Q4 24
$124.1M
$-266.8M
Q3 24
$35.8M
$-63.6M
Q2 24
$28.0M
$-70.7M
Q1 24
$31.3M
Free Cash Flow
AMAL
AMAL
PHAT
PHAT
Q4 25
$134.4M
$-167.0M
Q3 25
$38.3M
$-14.1M
Q2 25
$24.2M
$-62.8M
Q1 25
$32.5M
$-84.9M
Q4 24
$122.3M
$-266.9M
Q3 24
$35.2M
$-63.6M
Q2 24
$27.8M
$-70.8M
Q1 24
$31.1M
FCF Margin
AMAL
AMAL
PHAT
PHAT
Q4 25
157.8%
-290.0%
Q3 25
44.7%
-28.6%
Q2 25
29.9%
-159.0%
Q1 25
42.2%
-297.9%
Q4 24
157.0%
-899.8%
Q3 24
43.4%
-389.0%
Q2 24
35.4%
-966.2%
Q1 24
39.7%
Capex Intensity
AMAL
AMAL
PHAT
PHAT
Q4 25
1.6%
0.4%
Q3 25
1.4%
0.1%
Q2 25
0.9%
0.2%
Q1 25
2.3%
0.1%
Q4 24
2.3%
0.5%
Q3 24
0.7%
0.3%
Q2 24
0.3%
0.6%
Q1 24
0.3%
Cash Conversion
AMAL
AMAL
PHAT
PHAT
Q4 25
Q3 25
1.47×
Q2 25
0.96×
Q1 25
1.37×
Q4 24
Q3 24
1.28×
Q2 24
1.05×
Q1 24
1.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons